12.46 +0.36 (2.98%)
Pre-Market: 5:08AM EST
|Bid||11.84 x 1400|
|Ask||12.59 x 1000|
|Day's Range||10.80 - 12.60|
|52 Week Range||2.93 - 32.05|
|Beta (3Y Monthly)||3.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 24, 2020 - Feb 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.81|
On CNBC's "Mad Money Lightning Round," Jim Cramer said S&P Global Inc (NYSE: SPGI ) is a buy. He thinks the management team is terrific. Bank of America Corp (NYSE: BAC ) is going higher, said ...
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
By Jonathan Drimmer, Paul Hastings, and Yousuf Aftab, Enodo Rights & Atelier Aftab Amidst a spirited debate around the duties of directors in relation to environmental, social, and governance (ESG) risks, two recent decisions from Delaware courts provide clarifying contours. The decisions are particularly significant since Delaware is the leading state for corporate law and […]
Immunomedics (IMMU) resubmits BLA to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer, who have received at least two prior therapies.
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
Clovis (CLVS) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here are three stocks with continued technical momentum in the days and weeks after strong earnings releases. Clovis Oncology, Inc . (NASDAQ: CLVS ) jumped 75 cents to $7.76 on 8.1 million shares Thursday. ...
Here are three stocks with continued technical momentum in the days and weeks after strong earnings releases. Clovis Oncology Inc. (CLVS) jumped 75 cents to $7.76 on 8.1 million shares traded Thursday.
The number of pharmaceutical and biotechnology companies seeking Chapter 11 protection has nearly tripled the 10-year average in 2019 and is expected to continue to rise Continue reading...
BOULDER, Colo.-- -- Rubraca ® offers a new monotherapy maintenance treatment option for eligible women with relapsed, platinum-sensitive ovarian cancer, who harbor either a BRCA1/2 mutation or are BRCA wild-type Rucaparib provided statistically significant improvement in progression-free survival versus placebo in all ovarian cancer patients studied 1 Some patients with residual disease at ARIEL3 study ...
With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Clovis Oncology Inc (NASDAQ:CLVS). Clovis Oncology Inc (NASDAQ:CLVS) was in […]
Clovis (CLVS) delivered earnings and revenue surprises of 1.56% and 3.56%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
BOULDER, Colo.-- -- $37.6M in Rubraca ® net product revenue for Q3 2019, up 65% year over year Net product revenue increased 14% sequentially in Q3 2019 compared to Q2 2019, including sequential U.S. sales increase of 12% Increased FY2019 global net product revenue guidance to $141M-$147M Q3 2019 operating cash burn reduced from Q2 2019 by 42%; net cash burn reduced to $45M $354.1M in cash, cash equivalents ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally ...
Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clovis Oncology, Inc. will announce its third quarter 2019 financial results on Thursday, November 7, 2019, before the open of the U.S. financial markets. Clovis’ senior management will host a conference call and live audio webcast at 8:30 a.m.